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Abstract 
Cardiovascular disease (CVD) is one of the most common diabetes-associated complications, as well as a leading 
cause for death in type 2 diabetes patients (T2D). Despite the well-known correlation between the two, up until 
the 2008 FDA industry guidance for licensing of new anti-hyperglycemic drugs, which required an investigation 
of cardiovascular outcomes (CVO) of glucose-lowering agents, only a few studies had looked into the relationship 
between glucose lowering drugs and cardiovascular (CV) risk. Thereafter, CVOT design has focused on non-inferiority 
short-term studies on high-risk patient populations aiming at capturing CV safety issues. Despite the wealth of infor-
mation and useful data provided by CVOTs, this approach still suffers from certain limitations. The present review will 
condense the main results of the most recently completed CVOTs, reflect on the lessons learned, discuss on the issues 
presented by current CVOT design and offer some suggestions for improvement.
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Background
Among diabetes-related complications, cardiovascular 
disease (CVD) stands as the leading cause for mortal-
ity and adverse outcomes in patients with type 2 diabe-
tes (T2D). More than 60 % die from CVD while an even 
greater proportion suffer serious CV-associated compli-
cations [1]. T2D implies a two to fourfold increase in the 
risk of coronary heart disease and a decreased life expec-
tancy (6–7  years less) in comparison with people with-
out diabetes [2]. Despite this clear correlation between 
diabetes and negative CV outcomes, it is still not clear 
whether glycemic control per se would have any effect on 
reducing CVD risk in T2D [3–6]. Moreover, CV safety 
of glucose-lowering drugs was not thoroughly investi-
gated until the 2008 US Food and Drug Administration 
(FDA) [7] and subsequent European Medicines Agency 
(EMA) requirement [8] that all new therapies for diabe-
tes undergo a rigorous assessment of CV safety through 
large-scale cardiovascular outcome trials (CVOT).
Before the publication of the FDA and EMA regula-
tions, several trials assessing CV risks of glucose-low-
ering interventions had already been performed, if only 
with concerns in respect to design since they were aimed 
towards an improvement of glycemic control and out-
come analysis [6]. For instance, in 1970 the first multi-
center, head to head trial (University Group Diabetes 
Program) of T2D glucose-lowering treatments assessing 
CV outcomes was interrupted, as all oral drugs (tolbuta-
mide, phenformin) seemed to increase CV risk in com-
parison to placebo or insulin [9–11]. However, this trial 
was grossly underpowered and therefore results often 
contested. Later, the 1977 UKPDS trial randomized 
patients to either standard or intensive diabetes care 
with either insulin, sulphonylurea or metformin. After 
10  years, there was a significant reduction of MI risk 
and all-cause mortality in the intensive therapy group 
with any of the three drugs. However, the reduction of 
CV-associated risk was greater with metformin (39  % 
MI, 36  % all-cause) than with insulin or sulphonylurea 
(15  % MI, 13  % all-cause) [12]. A later meta-analysis of 
randomized trials using metformin found highly diverse 
results in terms of mortality risk increase/reduction as 
well as possible CV deleterious effects of a metformin/
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sulphonylurea combination [13], which were found to be 
greatly diminished 10 years after the end of the study and 
no longer statistically significant [14].
Other trials have found no differences in CV risk 
between glucose-lowering treatment interventions, as 
was the case for the HEART2D [15] trial, which com-
pared basal and prandial insulin treatment strategies or 
the BARI 2D [16] trial, that compared insulin-sensitizing 
and insulin-providing treatment strategies in patients 
with T2D and CVD. However, the HEART2D trial was 
clearly underpowered, and a post hoc analysis seems 
to suggest a positive effect of controlling postprandial 
hyperglycemia in some subgroups of subjects, like older 
patients [17, 18]. The more recent ORIGIN trial, [19] 
which randomized patients with prediabetes and T2D 
patients with CVD risk factors to either insulin glargine 
or standard glucose control did also not find any differ-
ences to the primary CV outcome between treatment 
groups.
Several compounds have been suggested to increase 
CV risk in diabetes. For instance, several inter-related 
meta-analyses infer that rosiglitazone might raise MI and 
heart failure (HF) risk [20, 21]. Despite the RECORD trial 
[22, 23] only showed an excess HF risk without any con-
clusive results on MI, a meta-analysis including RECORD 
data still concludes that the high risk/benefit ratio of 
rosiglitazone does not support its use for diabetes treat-
ment [21, 24]. The PROactive trial [25] on the CV safety 
of the addition to usual care of pioglitazone versus pla-
cebo found a slight trend toward a combined primary CV 
end-point—CVD and interventions in all vascular beds 
reduction—(10 % reduction, p = 0.095) and a significant 
16  % reduction in the secondary end-point (MI, stroke, 
all-cause mortality). However, increased HF rates and 
a number of severe associated adverse events have hin-
dered its use in daily practice [26, 27].
The requirements for CVOTs described in the afore-
mentioned 2008 FDA guideline include, among others 
[28]:
  • For outcome clinical trials, in order to exclude 
unacceptable CV risk, a two-sided 95  % CI upper 
boundary of 1.8 risk ratio (pre-approval) and/or 1.3 
risk ratio (post-approval) for major adverse events 
(MACE) versus control group is required.
  • To satisfy the new statistical requirements, CV event 
analysis might include a meta-analysis of all placebo-
controlled, add-on (drug vs. placebo, plus standard 
therapy) and active-controlled trials, and/or an addi-
tional single, large, safety CVOT can be conducted. 
This, alone or in addition to other trials, needs to 
satisfy the upper bound mentioned above before 
approval.
  • Patient selection should focus on high-risk popula-
tions, including those with advanced disease, elderly 
and those with renal impairment.
  • Trials must include at least 2 years of CV safety data.
  • A prospective independent adjudication of CV 
events in phase 2 and 3 studies must also be per-
formed. These CV events include CV mortality, 
myocardial infarction (MI) and stroke, and possibly 
hospitalization for ACS, urgent revascularization and 
other end-points.
Figure 1 includes a representation of possible scenarios 
for approval of new glucose lowering drugs depending on 
the hazard ratios (HR) for CV risk. An upper bound of 
the two-sided 95 percent confidence interval for the esti-
mated increased risk above the non-inferiority bound-
ary of 1.3 as well as underpowered studies prevents FDA 
approval. Surely, the need for full compliance with FDA/
EMA requirements on CV safety for approval of new glu-
cose lowering drugs has implied a significant increase of 
CVOTs in the last decade [28].
Results from early trials evaluating CV outcomes under 
glucose-lowering therapies could not ascertain a clear 
relationship between HbA1c target levels, hypoglycemia 
incidence and CV risk, despite a tendency for intense 
glucose control being beneficial in the long-term [6, 
Fig. 1 Confidence interval (CI) bars indicated by FDA guideline. 
Shown are five examples of hazard ratios (HR) and the upper limit 
of the 95 % CI of a development plan and regulatory consequences 
of each outcome. S superiority, NI non-inferiority, I inferiority, UP 
underpowered
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29–39]. Therefore, to avoid confounding results derived 
from glycemic values and the drugs themselves, CVOTs 
started after the 2008 FDA/EMA regulation have focused 
on maintaining glycemic equipoise, generally in the con-
text of standard diabetes care [40].
In the present review, we will summarize the latest 
results of CVOTs on glucose-lowering agents started 
after the 2008 FDA Guideline as well as present an out-
line of ongoing CVOTs. Furthermore, we will review 
their influence on present glucose lowering therapy deci-
sion-making as well as comment on CVOT design limita-
tions and potential venues for improvement.
Summary of results of recently completed CVOTs
Since the FDA and EMA guidance request for CV safety 
for new antihyperglycemic drugs, over 15 medium/
long-term CVOT have been initiated (see Table  1). 
From those, results for seven are already available while 
the remaining will be due by 2020 latest. In compari-
son to clinical trials on anti-hyperglycemic drugs per-
formed prior to 2008, patient numbers have considerably 
increased (more than five times on average). So has the 
average number of countries per trial (1.6 times average), 
helping produce wider range data on other ethnic groups 
as well as in practice variation [6, 41, 42], while follow-up 
time remains on an average of 2.5 years [43–50].
Hereon we summarize the findings of all CVOTs started 
after the 2008 FDA guideline published to date, namely 
the SAVOR-TIMI, TECOS, ELIXA, EXAMINE, EMPA-
REG OUTCOME, LEADER and SUSTAIN-6 trials [44–
52]. Despite the focus on high-risk patients (a requirement 
for CVOT design), which poses a problem for extrapola-
tion of results to the general patient population, the cri-
teria for patient selection varied from trial to trial. For 
instance, age requirements of EXAMINE and EMPA-
REG OUTCOME included all patients over 18  years 
old, while in other trials minimum age ranged between 
30 and 50  years old. Cardiovascular risk also differed in 
each trial. While for most a preexisting CVD or CVD risk 
factors were necessary for enrolment, in the EXAMINE 
and ELIXA trials only patients already recovering from 
an acute coronary syndrome (ACS) were included in the 
study. For a detailed view on patient selection criteria, see 
Table 2. Moreover, an important aspect of CVOTs is that 
the evaluation of CV safety of the new glucose lowering 
drugs takes place in the background of diabetes and CVD 
standard care. This poses an important difference with 
respect to early trials like the UKPDS, performed before 
modern blood pressure reducing drugs; statins and an 
active attitude to coronary revascularization were part of 
routine care. Therefore, in Table  3 we have summarized 
the baseline concomitant medication of patients enrolled 
in trials started after 2008.
For clarity, results for each outcome will be split into 
distinct sections, starting by the primary composite end-
point and then proceeding to each of the possible CV 
outcomes evaluated by these trials: MI, unstable angina 
(UA), CV death and HF. Finally, we will review a few 
other relevant safety end-points, namely: pancreatitis, 
hypoglycemia occurrence, and renal events/microvascu-
lar effects
  • Primary MACE composite end-point Diverse individ-
ual elements are included in the primary composite 
end-point for each CVOT, as shown in Table 1. How-
ever, CV death, myocardial infarction and stroke are 
all common elements to primary composite CVOT 
end-points. In addition, the TECOS and ELIXA tri-
als included hospitalization for UA in the primary 
MACE. Corresponding data in Table  4 shows that 
for saxagliptin (SAVOR-TIMI), sitagliptin (TECOS), 
lixisenatide (ELIXA) and alogliptin (EXAMINE) 
treatment, occurrence of the primary composite 
end-point did not differ from placebo groups, thus 
confirming non-inferiority of the new treatments in 
CV safety under the particular conditions of each 
of the trials. In the EMPA-REG OUTCOME trial, 
however, the primary outcome occurred in 10.5  % 
in the pooled empagliflozin group and in 12.1  % of 
the placebo group (empagliflozin group (HR 0.86; 
95  % CI 0.74–0.99; p  =  0.04 for superiority), dem-
onstrating therefore not only non-inferiority versus 
placebo but superiority [49]. A similar result was 
observed in LEADER, where the primary outcome 
occurred in significantly fewer patients in the liraglu-
tide group than in the control group (13 vs. 14.9 %; 
HR 0.87; 95  % CI 0.78–0.97; p =  0.01 for superior-
ity), but only for patients with established CVD (sub-
group analysis) [51]. It is important to note, however, 
that both in LEADER and EMPA-REG OUTCOME, 
the lesser occurrence in the primary composite end-
point was largely driven by a reduction in cardiovas-
cular mortality. Results from the recently published 
SUSTAIN-6 trial have also shown superiority for 
semaglutide versus placebo in the primary compos-
ite outcome (6.6 vs. 8.9  % of patients, respectively; 
HR: 0.74, 95 % CI 0.58–0.95; p < 0.001), however, in 
contrast to EMPA-REG OUTCOME and LEADER, 
results were not driven by a decrease of risk of car-
diovascular death, but of non-fatal stroke occur-
rence (in 1.6 and 2.7 %, respectively (HR 0.61; 95 % CI 
0.38–0.99; p = 0.04) [52].
  • Cardiovascular death In all terminated trials, treat-
ment with the new agent did not increase CV death 
compared to placebo treatment. In addition, in the 
EMPA-REG OUTCOME and LEADER trials, the 
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Table 1 Basic characteristics of CVOTs started after 2008 FDA regulation
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empagliflo-
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Table 1 continued
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Table 2 Characteristics of patients enrolled in CVOTs referred to in the text
AHA anti-hyperglycemic agents
Age Diabetes type HbA1c levels Cardiovascular status Prior antihyperglycemic treat-
ment
BMI (kg/m2)
SAVOR-TIMI53 ≥40 T2DM ≥6.5 % CVD OR high CV risk AHA 31.1
EXAMINE ≥18 T2DM (6.5, 11.0 %) ACS (15, 90) days before AHA 28.7
TECOS ≥50 T2DM (6.5, 11.0 %) preexisting CVD AHA 30.2
ELIXA ≥30 T2DM ≥7.0 % ACS min. 180 days before AHA 30.2
EMPA-REG 
OUTCOME
≥18 T2DM (7.0, 10.0 %) Preexisting CVD Drug näive OR AHA ≤45
LEADER ≥50 T2DM ≥7.0 % Preexisting CVD/cerebrovascu-
lar disease/vascular disease/
renalORheart failure at ≥50 OR 
CV risk at ≥60
Drug näive OR AHA 32.5
SUSTAIN-6 ≥50 T2DM ≥7.0 % Preexisting CVD at ≥50 OR 
preCVD at ≥60
Drug näive OR AHA 31.1
EXSCEL ≥18 T2DM (7.0, 10.0 %) Specific AHA
CAROLINA ≥40 ≤85 T2DM (6.5, 7.5–8.5 %) CVD OR specified diabetes 
end-organ damage OR age 
≥70 years OR ≥2 specified CV 
risk factors
≤45
REWIND ≥50 T2DM ≤9.5 % Preexisting vascular disease OR 
≥CV risk factors
AHA
ITCA650 ≥40 T2DM ≥6.5 % Preexisting coronary, cerebro-
vascular or peripheral artery 
disease
DECLARE-TIMI ≥40 T2DM High risk CV events
CARMELINA ≥18 T2DM (6.5, 10.0 %) High risk CV events Drug näive OR specific AHA ≤45
DEVOTE ≥50 T2DM ≤7.0 % CVD OR renal disease OR ≥60 
CV risk
Specific AHA
MK-3102 ≥40 T2DM (6.5, 10.0 %) Preexisting vascular disease
Ertugliflozin trial ≥40 T2DM (7.0, 10.5 %) Preexisting vascular disease Drug näive OR AHA ≥18
TOSCA-IT ≥50 ≤75 T2DM (7.0, 9.0 %) Specific AHA 20–45
CANVAS ≥40 T2DM (7.0, 10.5 %) Preexisting CVD OR high CV risk Drug näive OR AHA
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treatment group showed a reduced incidence of CV 
death in comparison to placebo [49, 51, 53, 54].
  • Fatal/non-fatal myocardial infarction An important 
CV outcome to measure given the increased MI risk 
implied by diabetes [55], therefore its inclusion in all 
primary composite MACE end-points. Data from 
the six trials published to date has shown that all 
glucose-lowering treatments tested are non-inferior 
to placebo when it comes to MI. For a more detailed 
comparison of hazard rates, see Table 4.
  • Stroke In general, the third basic element of primary 
composite MACE end-points. So far, considering 
the published results of the aforementioned six tri-
als, none of the new glucose-lowering drugs tested 
increases stroke occurrence in comparison to pla-
cebo. However, in EMPA-REG OUTCOME a trend 
towards an increased stroke incidence was reported 
[49]. Conversely to EMPA-REG OUTCOME, in 
SUSTAIN-6, a significant reduction of stroke rates 
was reported for patients under semaglutide in com-
parison to the placebo group [52]. For more data on 
hazard rates, see Table 4.
  • Hospitalization for UA The importance of this end-
point varied among trials. While TECOS and ELIXA 
included UA in their primary end-points; and 
SAVOR-TIMI, EMPA-REG OUTCOME and EXAM-
INE included it as part of the secondary composite 
end-point, LEADER and SUSTAIN-6 included it as 
part of an extended primary composite end-point. 
As it happened with MI or stroke risk, UA rates did 
not increase under any of the treatments investigated 
when compared to placebo. Extended information is 
available on Table 4.
  • Hospitalization for HF As shown in Table 4, rates of 
hospitalization for HF did not differ between placebo 
and treatment groups in the EXAMINE, TECOS, 
ELIXA or SUSTAIN-6 trials, and LEADER showed 
a non-significant decrease of hospitalization for HF 
in patients treated with liraglutide [51]. Yet, treat-
ment with saxagliptin (SAVOR-TIMI) was found to 
increase hospitalization rates for HF (3.5 vs. 2.8  %; 
HR 1.27; 95  % CI 1.07–1.51; p =  0.007). This effect 
was independent of age, as confirmed by a later 
analysis on efficacy and safety in older patients [43]. 
Conversely, in EMPA-REG OUTCOME treatment 
with empagliflozin reduced the number of patients 
hospitalized for HF (2.8 vs. 4.5 %; HR 0.61; 95 % CI 
0.47–0.79; p  <  0.001) and improved other HF out-
comes like the composite endpoint of CV death or 
hospitalization for HF (5.7 vs. 8.5 %; HR 0.66; 95 % CI 
0.55–0.79; p < 0.001) [45, 53].
  • Serious hypoglycemic events As part of the serious 
adverse event report, the rate of serious hypogly-
cemic events suffered by patients under treatment 
with the new glucose lowering drugs was investi-
gated. Even though rates were similar to placebo in 
all CVOTs, and major hyperglycemia events did not 
differ between saxagliptin (SAVOR-TIMI) treat-
ment and placebo, hypoglycemia occurrence gener-
ally increased with saxagliptin in combination with 
sulphonylureas or insulin. This effect was consistent 
across all age ranges analyzed [43]. On the contrary, 
treatment with liraglutide reduced severe hypogly-
cemic events in comparison to placebo (rate ratio: 
0.69; 95  % CI 0.51–0.93; p =  0.02), which might be 
due to a reduced need for insulin co-therapy [51]. In 
Table 3 Concomitant medication at baseline in CVOTs referred to in the text

















SAVOR-TIMI53 6757 (40.9) 11,094 (67.4) 6332 (38.5) 12,390 (75.2) 12,892 (78.3) 13,386 (81.3) 10,117 (61.4) 12,935 (78.5) 6730 (40.9)
EXAMINE 1605 (29.8) 3562 (66.2) 2503 (69.9) 4881 (90.7) 4866 (90.4) 5232 (97.2) 4411 (81.9) 4411 (81.9) 1197 (22.2)
TECOS 3408 (23.2) 11,966 (81.6) 6645 (45.3) 11,518 (78.5) 11,719 (79.9) 3167 (21.7) 9322 (63.5) 11,555 (78.8) 4961 (33.8)
ELIXA 2292 (37.8) 3834 (63.2) 1863 (30.7) 5726 (94.4) 5621 (92.6) 480 (7.9) 5119 (84.4) 5151 (84.9) 1327 (21.9)
EMPA-REG 
OUTCOME
2394 (34)a 3933 (55.9)a 1383 (19.6) 5990 (85) 5387 (77) – 4537 (64) 5651 (80) 2114 (30)
LEADER 3905 (41.8)a 7136 (76.4) 4721 (50) 6523 (69.8) 6729 (72) 6322 (67.7) 5173 (55.4) 4761 (51) 920 (9.85)
SUSTAIN-6 1913 (58.0) 2414 (73.2) 1410 (42.8) 2108 (63.9) 2399 (72.8) 406 (12.3) 1894 (57.4) 1642 (49.8) 258 (7.8)
CAROLINA – 4982 (82.5) 1728 (28.6) 3026 (50.1) 3872 (64.1) – 2344 (38.8) 2664 (44.1) 1770 (29.3)
CANVAS 2171 (50.1) 3158 (72.9) 2032 (46.9) 3119 (72.0) 3073 (71.0)
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SUSTAIN-6, the rates of severe hypoglycemia did not 
significantly differ between the two semaglutide-dose 
treatment groups and placebo [semaglutide 0.5  mg 
and 1.0  mg 191 (23.1  %) and 178 (21.7  %), respec-
tively], placebo 0.5 and 1.0 mg [177 (21.5 %) and 173 
(21.0 %)] [52].
  • Pancreatic effects Regarding the possible association 
between incretin-based therapies and adverse pan-
creatic effects, CVOTs evaluated whether these new 
antihyperglycemic agents increased the risk for pan-
creatitis. Acute pancreatitis occurred slightly more 
often in the treatment groups than with placebo 
when employing saxagliptin (SAVOR-TIMI), sitaglip-
tin (TECOS), alogliptin (EXAMINE) or lixisenatide 
(ELIXA), and even when no significant differences 
between groups could be found, a meta-analysis 
on trials on DPP-4 inhibitors showed a marginally 
higher risk of pancreatitis associated with DPP-4 
treatment [56]. In LEADER and SUSTAIN-6, inci-
dence of pancreatitis was lower, even if not statisti-
cally significant, in the intervention group than in the 
placebo group [51, 52].
  • Renal events and/or microvascular effects Definitions 
for renal events were different for each trial. While 
in the ELIXA and TECOS trials there is no specifi-
cation of the type of renal events [44], in EXAMINE 
only initiation of dialysis is reported [47]. A broader 
renal end-point including doubling of creatinine 
level, initiation of dialysis, renal transplantation or 
creatinine >6.0 mg/dl was used in the SAVOR-TIMI 
trial [43]. Regardless of end-point definition, none of 
these trials found differences between treatment and 
placebo with respect to renal function. Moreover, a 
further examination of the EMPA-REG OUTCOME 
trial regarding renal outcomes, found that addition 
of empagliflozin to standard treatment was associ-
ated with a slower progression of kidney disease 
(empagliflozin HR 0.61; CI 95 % 0.53–0.70; p < 0.001) 
and lower rates of clinically relevant renal events 
than placebo [57]. In the LEADER trial, a composite 
renal and retinal microvascular outcome was inves-
tigated. The renal outcome involved the new onset 
of macroalbuminuria or the doubling of the serum 
creatinine level and an eGFR ≤45  ml/min/1.73  m2, 
the need for continuous renal-replacement therapy 
or death from renal disease. The incidence of the 
composite microvascular outcome was lower with 
liraglutide, mainly due to a significantly lower rate 
of nephropathy events (HR 0.78; 95 % CI 0.67–0.92; 
p  =  0.003) [51]. In SUSTAIN-6, the investigated 
renal outcome was defined as new or worsening of 
nephropathy and consisted on persistent macroalbu-
minuria, persistent doubling of the serum creatinine 
level and eGFR ≤45 ml/min/1.73 m2, or the need for 
continuous renal-replacement therapy. Based on that 
definition, semaglutide treated patients had a signifi-
cantly lower risk than placebo treated patients (3.8 
vs. 6.1  %, respectively; HR 0.64; 95  % CI 0.46–0.88; 
p = 0.005). Conversely, and somehow unexpectedly, 
retinopathy-derived complications (blindness, vitre-
ous hemorrhage, or conditions requiring treatment 
with an intravitreal agent or photocoagulation) were 
significantly more often reported in the treatment 
group as in the placebo (3.0 vs. 1.8  %, respectively; 
HR 1.76; 95 % CI 1.11–2.78; p = 0.02) [52].
In general, the previous analysis shows that new glu-
cose lowering drugs comply with FDA/EMA require-
ments for CV safety regardless of class. Moreover, some 
of them like empagliflozin, liraglutide or semaglutide 
even demonstrated beneficial effects over CV death risk, 
stroke and/or HF risk [49, 51–53].
Discussion
CVOT trials completed after 2008 showed that new 
glucose lowering agents like the DPP-4 inhibitors saxa-
gliptin, alogliptin, and sitagliptin and the GLP-1 recep-
tor agonist lixisenatide are safe with respect to CV 
outcomes in high CV risk patient populations with long 
T2D duration (for more details on patient selection, see 
Table 2) under standard care for both CVD and diabetes. 
In addition, the LEADER study has shown that liraglu-
tide, a GLP-1 receptor agonist, is not only safe but that 
is also capable of reducing CV risk and the incidence of 
cardiovascular-related death [51]. Furthermore, recently 
published results from SUSTAIN-6 have proven another 
GLP-1 receptor agonist, semaglutide, superior to pla-
cebo in reducing the risk of a cardiovascular composite 
primary end-point, driven by a significant reduction of 
stroke risk [52]. Moreover, treatment with the SGLT-2 
inhibitor empagliflozin was not only non-inferior to pla-
cebo but also significantly reduced CV risk -as shown by 
the composite primary and secondary outcomes- and a 
composite outcome of HF hospitalization and CV death 
[53, 54].
Regardless of the CV safety of all anti-hyperglycemic 
agents tested, one trial on DPP-4 inhibitors, SAVOR-
TIMI, found a significantly higher risk for HF in the treat-
ment group and another, EXAMINE a trend towards such 
outcome. In contrast, there were no such concerns in the 
TECOS trial. Differences to baseline patient characteris-
tics, as well as to trial design make it difficult to compare 
results from these trials. Moreover, the molecular struc-
ture differs among DPP-4 inhibitors and so does their 
safety profile. As a result, the FDA recently issued a safety 
warning on saxagliptin and alogliptin increasing the 
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risk of heart failure, particularly in patients who already 
have heart or kidney disease [58]. Despite recent meta-
analyses of randomized clinical trials including results 
of SAVOR-TIMI and EXAMINE suggested an increased 
risk of hospitalization due to HF in T2D patients [59–62], 
others have found no difference in hospitalization rates 
for HF between treatment with saxagliptin compared 
with sitagliptin or with DPP-4 inhibitors compared with 
other classes of anti-diabetes agents [63, 64].
The analyses of results of the aforementioned CVOTs 
have been very useful for treatment decision-making and 
patient safety in diabetes [65]. Not only were these trials 
capable of proving CV safety, but three of them, EMPA-
REG OUTCOME, LEADER and SUSTAIN-6 showed 
cardiovascular benefits even when they were primarily 
designed for non-inferiority. However, it is important to 
note that these results are so far only valid for the par-
ticular patient groups enrolled in the studies, and that 
it is not clear how translatable they are to the general 
patient population. Furthermore, a comparison among 
results from CVOT is overall difficult, among other rea-
sons because the definition of CVD risk and/or CVD is 
different for each trial, and with it the degree of sever-
ity of prior disease of enrolled patients highly variable. 
Other reasons limiting comparability among CVOTs, 
especially in terms of event rates, apart from the afore-
mentioned differences in baseline patient characteristics, 
are the variable trial duration and the diverse definitions 
of the primary end-point. In addition, another obstacle 
for compared evaluation of trials evaluating cardiovas-
cular outcomes before and after FDA 2008 regulation 
is that the routine care background from those tri-
als is somehow dissimilar. In general, despite the great 
advance for the clinical practice meant by new CVOTs, 
there is still room for improvement [66, 67]. Trial design 
could still benefit from the introduction of new strate-
gies to improve the applicability of trial results to daily 
clinical practice, as was agreed by the members of the 
first CVOT Summit of the Diabetes and CVD (D&CVD) 
EASD Study Group [68].
Among the recommendations stand the necessary con-
sensus on primary end-point definition, which should be 
a 3-point MACE comprising cardiovascular death, non-
fatal MI and non-fatal stroke. Another important point is 
that these cardiovascular outcomes differ greatly in their 
pathophysiology: while MI has a thrombotic origin [69], 
CV death results mostly from arrhythmia [70] and stroke 
can either be a product of thrombotic origin or hemor-
rhagic [71, 72]. These differences should be taken into 
account when designing and analyzing composite MACE 
end-points, because a positive/neutral effect in one of the 
components does not necessarily mean an improvement 
in the others, especially when considering their particular 
pathophysiology, as exemplified by the results of the vari-
ous components of the primary composite end-point in 
EMPA-REG OUTCOME [49, 53]. Moreover, and espe-
cially regarding the disparate results on HF risk in DPP-4 
inhibitor trials, HF risk should be investigated more 
closely by CVOTs [68, 73].
A major issue of CVOT design to date is patient selec-
tion criteria. Disease duration is a potential confounding 
factor that is not sufficiently controlled [74]. On the other 
hand, extrapolating CV results from this patient popu-
lation to a broader one can be challenging, especially 
in case of superiority to placebo. To solve this matter, 
potential solutions could be: increasing patient reten-
tion/adherence to treatment over longer follow-up peri-
ods, promote large-scale patient enrolment by involving 
patient advocacy groups and modifying trial design to 
new approaches that minimize patient numbers and pro-
vide closer to real-world data in the standard health care 
system [6, 68].
Another limitation of the present CVOTs is that trial 
duration is too short to evaluate real-life, long-term out-
comes [74], plus incurring in an unjustified high cost 
per patient given the limited results they provide. The 
extreme cost of CVOTs make them only accessible to 
industry and hinders an independent CV risk review 
[6]. To increase the amount of available data by enabling 
extensive follow-up and reduce trial related costs, an 
alternative would be to make use of comprehensive elec-
tronic health record databases with extended functional-
ity [75, 76].
Maintaining glycemic equipoise, by addition of the test 
agent to standard care, has resulted in general in modest 
HbA1c reductions, which combined with the short fol-
low-up time of most studies, makes it hard to positively 
ascertain CV benefit of these glucose-lowering drugs 
[40]. On the other hand, maintaining glycemic equipoise 
but aiming to longer follow-up times might still result 
in CV improvement by incidental effects from these 
drugs other than glycemic control, as was the case in the 
EMPA-REG OUTCOME trial.
Most CVOTs started after the 2008 FDA/EMA guide-
line analyze drugs of the SGLT-2 inhibitor, DPP-4-in-
hibitor, or GLP-1 receptor agonist class. Even when the 
ORIGIN trial already focused on the evaluation of insulin 
gargline versus standard care [19], since the FDA man-
date only one CVOT study is investigating CV risks of 
insulin treatment, the ongoing DEVOTE trial on insulin 
glargine versus insulin degludec. To date there is not a 
single CVO trial on metformin or sulphonylurea alone. 
Considering that metformin is a first line treatment for 
T2D [77] and that sulphonylurea and insulin are also very 
common therapeutic tools in diabetes [78], more CVOTs 
on these drugs are essential.
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Furthermore, present CVOTs are usually simple, pla-
cebo controlled, non-inferiority trials and generally 
lacking of head to head comparisons. Exceptionally, the 
ongoing CAROLINA trial includes a head to head com-
parison of safety issues of linagliptin, a DPP-4 inhibitor, 
versus a sulphonylurea (glimepiride) [79]. In the future, 
trial design should be aimed at matching results of several 
different treatment versus a reduced placebo group and 
ideally, under usual care. This strategy will not only allow 
for a direct treatment comparison but also enable a better 
assessment of treatment heterogeneity and possible drug 
interactions in the real population under standard of care 
[6, 68]. This strategy was followed by a recently termi-
nated cohort study comparing head to head CV safety 
of GLP-1 receptor agonists to DPP-4 inhibitors, sulfony-
lureas, or insulin in addition to metformin, in a similar 
fashion to real-world conditions [80].
Despite including analysis of adverse outcomes other 
than CV risks, in the future a more thorough examination 
of microvascular complications, renal, kidney and pancre-
atic effects as well as cancer occurrence should be an inte-
gral component of a CVOT design [68]. Already a number 
of trials have been designed with this concept in mind. For 
instance, an ongoing clinical trial (NCT02380521) exam-
ines the effect of exenatide once weekly, a GLP-1 recep-
tor agonist, on several CV risk markers like subclinical 
atherosclerosis, endothelial dysfunction, oxidative stress 
and atherogenic lipoproteins, which are also indicative of 
potential microvascular complications [81]. The ongoing 
CARMELINA trial (NCT01897532) also aims to charac-
terize renal microvascular outcomes of linagliptin (DPP-4 
inhibitor) on T2D patients at high CV risk. Moreover, 
another ongoing trial (CANVAS-R), focuses on the renal 
outcomes of canagliflozin (a SGLT-2 inhibitor) treatment 
on T2D patients at risk for CVD [82].
Conclusion
Since the 2008 FDA/EMA regulations demanded an 
investigation of CV outcomes for newly developed glu-
cose-lowering agents, a number of CVOTs have been 
completed and their results published. These trials, in 
general, have shown that glucose-lowering drugs do 
not increase CV risks over placebo levels, and even that 
some drugs, as empagliflozin, semaglutide or liraglutide, 
can actually lead to cardiovascular protection. However, 
despite satisfying the requirements of regulatory agencies 
when it comes to demonstrating not incrementing CV 
risk beyond a certain safety level, current CVOTs suffer 
still from certain design flaws that hinder their potential. 
Head to head comparisons, broader patient population 
groups, long-term analysis and an expansion of safety 
end-points, etc. would serve to improve CVOT design 
and expand its applicability spectrum.
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